Renal and bone safety of tenofovir alafenamide (TAF)-containing regimens in...
Renal and bone safety of tenofovir alafenamide (TAF)-containing regimens in treatment naïve HIV-infected patients were compared with tenofovir...
24 Sep, 2018
A recent meta-analysis demonstrated better hepatitis B virus (HBV) suppression, serum alanine aminotransferase (ALT) normalization rate, hepatitis B...
19 Sep, 2018
A recent pilot study determined the feasibility of dried blood spots (DBS) under certain conditions as sample type for HIV drug resistance (HIVDR)...
14 Sep, 2018
A recent meta-analysis evaluated the effectiveness of second-line antiretroviral therapy (ART) with lopinavir/ritonavir (LPV/r) (preferred or...
11 Sep, 2018
This study compared the enhanced and standard antimicrobial prophylaxis treatment in patients with advanced HIV disease.
Pre-exposure Prophylaxis Initiative (iPrEx) trial was a randomized, double-blind, placebo controlled trial aimed to evaluate the safety and efficacy...
The Partners PrEP Study is a double-blind, placebo-controlled, phase III clinical trial aimed to assess the safety and efficacy of oral PrEP for the...
Ritonavir -sparing regimens are recommended in patients intolerant to ritonavir, to minimise the long-term side effects and to improve lipid...
Today, antiretroviral therapy (ART) is not only known to keep HIV-infected patients alive but is also being harnessed as a strategy to prevent...
Advances in the treatment of HIV infection has resulted in a dramatic shift, from a deadly infectious disease to a chronic manageable condition....
Lopinavir and Ritonavir (40 mg / 10 mg) Oral Pellets is a Novel oral pellet formulation for paediatric use. This datasheet contains the entire...
Lopinavir and Ritonavir (40 mg / 10 mg) Oral Pellets is a Novel oral pellet formulation for paediatric use. This booklet contains information about...
This publication features commonly asked questions by HIV patients regarding HIV therapy, drug side-effects, Do’s and Don’ts while on HIV treatment...
This publication features common questions which arise in HIV patients mind regarding HIV, diagnosis, transmission, treatment and drug side effects...
This slide set covers the epidemiology, disease progression and management of HIV-HCV coinfection in the era of directly acting antivirals available...
PrEP is the use of an antiretroviral medication by HIV-negative individuals to prevent them from acquiring HIV. These slides give an overview on the...
Post-exposure prophylaxis (PEP) is the method of preventing exposures of HIV to blood and body fluids and it is considered to be the most important...
HIV is the strongest risk factor for developing tuberculosis (TB) disease in those with latent or new Mycobacterium tuberculosis infection....